icon-    folder.gif   Conference Reports for NATAP  
 
  18th CROI
Conference on Retroviruses
and Opportunistic Infections
Boston, MA
February 27 - March 2, 2011
Back grey_arrow_rt.gif
 
 
 
QDMRK, A Phase III Study of the Safety & Efficacy of Once Daily (QD) Versus Twice Daily (BID) Raltegravir (RAL) in Combination Therapy for Treatment-Naïve HIV-Infected Patients (Pts)
 
 
  Reported by Jules Levin
 
J. Eron1, J. Rockstroh2, J. Reynes3, J. Andrade4, J. Madruga5, J. Zhao6, P. Sklar6, B-Y. Nguyen6 for the QDMRK Study Team 1Univ. of North Carolina, Chapel Hill, NC, USA; 2Univ. of Bonn, Bonn-Venusberg, Germany; 3Montpellier Univ. Hospital, Montpellier, France; 4Universidad de Guadalajara, Mexico; 5Centro de Referencia DST/AIDS, Sao Paulo, Brazil and 6Merck Research Laboratories, North Wales, PA, USA

apasl1.gif

apasl2.gif

apasl3.gif

apasl4.gif

apasl5.gif

apasl6.gif

apasl7.gif

apasl8.gif

apasl9.gif

apasl10.gif

apasl11.gif

apasl12.gif

apasl13.gif

apasl14.gif